Please login to the form below

Not currently logged in
Email:
Password:

Convergence and Selcia enter collaboration

Newly launched biotech, Convergence Pharmaceuticals, and contract research organisation, Selcia, have entered into a collaboration aiming to discover molecules to treat chronic pain
Convergence Pharmaceuticals, a UK-based pharmaceutical company recently launched out of GlaxoSmithKline (GSK), and Selcia, a contract research organisation, have entered into a drug discovery collaboration aiming to identify and develop compounds for the treatment of chronic pain. 

Under the terms of the agreement, Convergence Pharmaceuticals will apply its ion channel biology platform, medicinal chemistry know-how and preclinical development expertise to Selcia's medicinal chemistry and chemistry support services. Financial terms were not disclosed. 

Commenting on the announcement, Dr Ged Giblin, head of chemistry and preclinical development at Convergence Pharmaceuticals, said: "We believe the combination of Convergence's platform and Selcia's bespoke approach will provide an innovative model for this drug discovery partnership in finding solutions for a major unmet clinical need."

In the UK alone, four out of five initial visits to the general practitioner (GP) involve pain as the primary symptom, and prescription rates for analgesic medications are the second highest. By 2023 the chronic pain market in the seven major pharmaceutical markets is predicted to reach over $47bn. In the same seven pharmaceutical markets, 160 million people are estimated to suffer from osteoarthritis, 36 million people from chronic lower back pain and sciatica and over 10 million from neuropathic (or nerve) pain.

23rd November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics